These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29193561)

  • 1. Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.
    Loughlin AM; Qiao Q; Nunes AP; Öhman P; Ezzy S; Yochum L; Clifford CR; Gately R; Dore DD; Seeger JD
    Diabetes Obes Metab; 2018 Apr; 20(4):898-909. PubMed ID: 29193561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States.
    Loughlin AM; Qiao Q; Nunes AP; Ezzy SM; Yochum L; Clifford CR; Gately RV; Dore DD; Seeger JD
    Diabetes Spectr; 2018 May; 31(2):129-137. PubMed ID: 29773932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care.
    Nunes AP; Loughlin AM; Qiao Q; Ezzy SM; Yochum L; Clifford CR; Gately RV; Dore DD; Seeger JD
    Diabetes Ther; 2017 Dec; 8(6):1349-1364. PubMed ID: 28983857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.
    Holden SE; Morgan CL; Qiao Q; Jenkins-Jones S; Berni ER; Currie CJ
    Diabetes Obes Metab; 2017 Aug; 19(8):1097-1105. PubMed ID: 28218819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All-cause and diabetes-related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine.
    Wittbrodt E; Kong AM; Moore-Schiltz L; Juneau P
    Diabetes Obes Metab; 2018 Mar; 20(3):672-680. PubMed ID: 29083520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
    Grimm M; Li Y; Brunell SC; Blase E
    Postgrad Med; 2013 Sep; 125(5):101-8. PubMed ID: 24113668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
    Clegg LE; Penland RC; Bachina S; Boulton DW; Thuresson M; Heerspink HJL; Gustavson S; Sjöström CD; Ruggles JA; Hernandez AF; Buse JB; Mentz RJ; Holman RR
    Cardiovasc Diabetol; 2019 Oct; 18(1):138. PubMed ID: 31640705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
    Grimm M; Han J; Weaver C; Griffin P; Schulteis CT; Dong H; Malloy J
    Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study.
    Morgan CL; Qiao Q; Grandy S; Johnsson K; Jenkins-Jones S; Holden S; Currie CJ
    Diabetes Ther; 2018 Feb; 9(1):269-283. PubMed ID: 29318537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
    Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
    Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
    Malloy J; Meloni A; Han J
    Postgrad Med; 2013 May; 125(3):58-67. PubMed ID: 23748507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
    van der Aart-van der Beek AB; van Raalte DH; Guja C; Hoogenberg K; Suchower LJ; Hardy E; Sjöström CD; Heerspink HJL
    Diabetes Obes Metab; 2020 Sep; 22(9):1556-1566. PubMed ID: 32329160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
    Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
    Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks.
    Diamant M; Van Gaal L; Stranks S; Guerci B; MacConell L; Haber H; Scism-Bacon J; Trautmann M
    Diabetes Care; 2012 Apr; 35(4):683-9. PubMed ID: 22357185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.
    Wang X; Zhang H; Zhang Q; Guan M; Sheng S; Mo W; Zou M; Li J; Bi J; Tang X; Zeng H; He J; Xu G; Li P; Xue Y
    Am J Nephrol; 2020; 51(10):806-814. PubMed ID: 32966971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis.
    Peskin BR; Shcheprov AV; Boye KS; Bruce S; Maggs DG; Gaebler JA
    Diabetes Obes Metab; 2011 Oct; 13(10):921-7. PubMed ID: 21624032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.
    Guja C; Frías JP; Suchower L; Hardy E; Marr G; Sjöström CD; Jabbour SA
    Diabetes Ther; 2020 Jul; 11(7):1467-1480. PubMed ID: 32306296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.
    Unni S; Wittbrodt E; Ma J; Schauerhamer M; Hurd J; Ruiz-Negrón N; McAdam-Marx C
    Diabetes Obes Metab; 2018 Feb; 20(2):468-473. PubMed ID: 28862808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
    Leiter LA; Carr MC; Stewart M; Jones-Leone A; Scott R; Yang F; Handelsman Y
    Diabetes Care; 2014 Oct; 37(10):2723-30. PubMed ID: 25048383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
    DeYoung MB; MacConell L; Sarin V; Trautmann M; Herbert P
    Diabetes Technol Ther; 2011 Nov; 13(11):1145-54. PubMed ID: 21751887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.